Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ

Reviewed 12 sourcesPublished by PepVault

Wegovy and Ozempic dosage side by side: both FDA labels' four-week steps, the maintenance doses and the max, why they differ and what the trials saw per dose.

A woman in a white tank top and navy skirt on a tennis court with a wooden racket
Last reviewed
Sources
12
Questions
6
Compounds
2

The short answer

Ozempic and Wegovy are the same drug, semaglutide, as a weekly shot. Both labels start at 0.25 mg for four weeks, then 0.5 mg. Ozempic, for type 2 diabetes, stays at 0.5, 1 or 2 mg, with 2 mg the maximum. Wegovy, for weight, climbs through 1 and 1.7 mg to 2.4 mg from week 17, and 7.2 mg is its top adult dose.

Every number checked at its primary source · · 12 sources · How we research

Evidence: FDA prescribing information for Ozempic and Wegovy, and the randomised trials behind them in people (SUSTAIN 1 and FORTE for Ozempic; STEP 1, 2 and 6, STEP UP and STEP UP T2D for Wegovy); semaglutide is FDA-approved.

A woman in a white tank top and navy skirt on a tennis court with a wooden racket

What are the Ozempic and Wegovy dose steps?

Both labels climb in steps of at least four weeks, a process called titration: starting low and raising the dose stepwise, which the labels use to lower the risk of stomach side effects12. The first eight weeks are identical. After that the two split, because Ozempic stops climbing once blood sugar is controlled and Wegovy keeps going toward a weight dose. This is the current US labelling (the DailyMed versions of June 10 and June 30, 2026)12.

WeeksOzempic (type 2 diabetes)Wegovy injection (weight)
1–40.25 mg, the starting dose10.25 mg, the starting dose2
5–80.5 mg10.5 mg2
9–120.5 mg, or 1 mg if more blood sugar control is needed after at least 4 weeks on 0.5 mg11 mg2
13–16Stays on the dose that controls blood sugar11.7 mg2
17 onward (maintenance)0.5 mg, 1 mg or 2 mg, chosen by blood sugar control; 2 mg only after at least 4 weeks on 1 mg12.4 mg (recommended) or 1.7 mg2
Maximum2 mg once weekly17.2 mg once weekly, for adults who have tolerated 2.4 mg for at least 4 weeks and need more weight loss2
Two dose staircases over 26 weeks: both start at 0.25 mg and step to 0.5 mg at week 5; from week 9 Ozempic stays at 0.5 mg or steps to 1 mg and later 2 mg by blood sugar, while Wegovy climbs to 1, 1.7 and 2.4 mg, with 7.2 mg possible from week 21
Look at week 9: the two labels share the first eight weeks, then Ozempic waits on blood sugar while Wegovy keeps climbing.

A maintenance dose is the dose kept once the climb is over. The 7.2 mg step is the newest: the FDA approved it as a new Wegovy dosing regimen on March 19, 202612. Each label also has one special case. Ozempic, for adults with type 2 diabetes and chronic kidney disease, moves to a 1 mg maintenance dose after at least four weeks on 0.5 mg1. Wegovy for children 12 and older stops at 2.4 mg or 1.7 mg, and for MASH, a form of fatty liver disease, the maintenance dose is 2.4 mg, with 1.7 mg if 2.4 mg is not tolerated2.

These are the labels' schedules, not a dose for any one person. The labels leave each step, and the maintenance dose, to the prescriber, weighing response and tolerability12. Wegovy also comes as a once-daily tablet with its own 30-day steps up to 25 mg2; our Wegovy pill guide covers it.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

Dose day and step: PepVault reminds you at the time you set and logs each weekly dose with the step-ups your prescriber set, as you enter them.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What rules do both labels share?

  • Once a week, same day: either shot goes in once a week on the same day, at any time of day, with or without meals12.
  • Under the skin of the belly, thigh or upper arm, with a different spot each week12.
  • Four weeks at least on a dose before the next step12. If a Wegovy step is not tolerated, the label suggests delaying the next one by four weeks2.
  • Changing the day: Ozempic's label allows it as long as at least two days (more than 48 hours) separate two doses1; Wegovy's lets the time of day and the injection site change without any dose change2.
  • Never two semaglutide products together: the Wegovy label does not recommend it with any other semaglutide product or any other GLP-1 drug2.

The missed-dose rules differ, and the missed-dose tool walks through both: Ozempic is taken within five days of the missed day, else skipped1; Wegovy is taken if the next dose is more than two days away, else skipped, and after two or more missed doses in a row the label restarts the climb at a lower dose2.

Why four weeks? Semaglutide has a half-life of about one week, the time the body takes to clear half a dose, so each weekly dose stacks on the last. The Ozempic label puts the steady level, where the weekly dose and the clearance balance, at four to five weeks of weekly dosing1. The chart shows how the level builds.

Try it

How Semaglutide builds up

An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.

Try your own scheduleSemaglutide in the library

When to get help If stomach symptoms turn severe or do not settle, both labels' advice is to contact your prescriber12.

Why are the Ozempic and Wegovy doses different?

Different jobs. The FDA approved Ozempic in December 201710 to improve blood sugar in adults with type 2 diabetes, and later to lower the risk of heart attack, stroke and cardiovascular death in those with heart disease, and of kidney decline in those with chronic kidney disease1. Wegovy, approved in June 202111, is for reducing excess weight and keeping it off, alongside diet and activity, plus heart-risk reduction in people with heart disease and obesity or overweight, and MASH2. Ozempic is not approved for weight loss; its label lists weight change as a trial result, not an indication1.

Different targets. At the top of the Ozempic range, more drug bought little extra blood sugar control: in SUSTAIN FORTE, 2 mg lowered HbA1c (the three-month blood sugar average) by 0.2 points more than 1 mg, and the 0.8 kg weight gap was not statistically significant19. For weight, the dose kept paying: in STEP 6, 1.7 mg averaged 9.6% of body weight lost and 2.4 mg 13.2%25.

Different pens. Ozempic comes in multi-dose pens: the 1 mg and 2 mg pens hold four weekly doses, and the starting pen holds four 0.25 mg doses and two 0.5 mg doses, or four 0.5 mg doses. It also comes in single-dose prefilled syringes of 0.25, 0.5 and 1 mg1. Wegovy comes mostly as single-dose pens and syringes, one fixed dose each from 0.25 mg to 2.4 mg; the 7.2 mg dose is a single-dose pen called Wegovy HD, and the Wegovy FlexTouch pen holds four 2.4 mg doses2. The strengths per mL differ between the two products, so a pen is only ever used for the doses printed on it, and a multi-dose pen is never shared, even with a new needle12.

What did the trials see at each dose?

The table prints the labels' figures, counted across everyone randomised whether or not they stayed on the drug; the papers, analysed slightly differently, give close numbers (STEP UP: 18.7% and 15.6%; SUSTAIN 1: HbA1c down 1.45 and 1.55 points)68. Weight change is the average from starting weight; HbA1c change is in percentage points. These are trial averages across groups, not what any one person can expect.

TrialWhoDose and lengthResult (against placebo or the lower dose)
SUSTAIN 18388 adults with type 2 diabetes on diet and exerciseOzempic 0.5 or 1 mg, 30 weeksHbA1c down 1.4 and 1.6 points against 0.1; weight down 3.8 and 4.7 kg against 1.2 kg1
SUSTAIN FORTE9961 adults with type 2 diabetes on metformin, some with a sulfonylureaOzempic 2 mg against 1 mg, 40 weeksHbA1c down 2.1 against 1.9 points; weight down 6.4 against 5.6 kg, a gap that was not statistically significant1
STEP 131,961 adults with obesity or overweight and a related condition, no diabetesWegovy 2.4 mg, 68 weeksDown 14.9% against 2.4%23
STEP 241,210 adults with overweight or obesity and type 2 diabetesWegovy 2.4 mg, 68 weeksDown 9.6% against 3.4%24
STEP 65401 East Asian adults with obesity or overweight and a related condition, a quarter with type 2 diabetesWegovy 1.7 or 2.4 mg, 68 weeksDown 9.6% and 13.2% against 2.1%25
STEP UP61,407 adults with obesity, no diabetesWegovy 7.2 or 2.4 mg, 72 weeksDown 18.8% and 15.5% against 3.9%2
STEP UP T2D7512 adults with obesity and type 2 diabetesWegovy 7.2 or 2.4 mg, 72 weeksDown 13.2% and 10.4% against 3.8%2
Average weight change in the Wegovy trials by dose: without diabetes, −14.9% (STEP 1) and −15.5% (STEP UP) on 2.4 mg and −18.8% on 7.2 mg; with type 2 diabetes, −9.6% (STEP 2) and −10.4% on 2.4 mg and −13.2% on 7.2 mg; STEP 6, a quarter with diabetes, −9.6% on 1.7 mg and −13.2% on 2.4 mg
Each dose step moves weight further, and at the same dose people with diabetes lose less.

Two patterns run through the table. More drug moved weight further at every step the trials tested, from 1.7 to 2.4 mg and from 2.4 to 7.2 mg2. And people with type 2 diabetes lost less at the same dose: 9.6% in STEP 2 against 14.9% in STEP 1 at 2.4 mg, two separate trials2. The Ozempic trials measured blood sugar first, and their weight results are a few kilograms over 30 to 40 weeks1.

What each week feels like on the Wegovy climb, from the first dose to the plateau, is in our guide Semaglutide week by week.

Commonly reported: the first weeks at 0.25 mg feeling like little is happening, appetite dropping more clearly from 0.5 or 1 mg, and nausea gathering in the days after each step-up before it eases.

Do the side effects change with the dose?

Mostly, yes, within each trial. On Ozempic, nausea was reported by 15.8% on 0.5 mg and 20.3% on 1 mg against 6.1% on placebo, most nausea, vomiting and diarrhoea came during the climb, and stomach side effects ran 34% on 2 mg against 30.8% on 1 mg1. On Wegovy in the STEP UP trials, nausea was 39% on 7.2 mg, 35% on 2.4 mg and 13% on placebo; the clearer rise at 7.2 mg was dysesthesia, an altered skin feeling such as tingling or burning, in 22% against 6% on 2.4 mg2. The semaglutide side-effects page and our Ozempic and Wegovy side-effects guide cover what helps with each one.

How do you keep track of the steps?

A schedule that changes every four weeks, on a drug taken once a week, is easy to lose count of. The GLP-1 titration calculator lays out the label's calendar from a start date. These are the records that keep it straight:

  • How each step sits: a note on nausea or appetite after each step-up gives you and your prescriber facts for deciding the next one.

Dose day and step: PepVault reminds you at the time you set and logs each weekly dose with the step-ups your prescriber set, as you enter them. Set reminders in PepVault

Weight: PepVault's weigh-in log draws your trend in pounds or kilograms, so each step's effect reads against the weeks around it. Track your weight in PepVault

Track it in the app

Sources

  1. OZEMPIC (semaglutide) injection prescribing information, DailyMed (SPL version 20), June 10, 2026 dailymed.nlm.nih.gov
  2. WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed (SPL version 19), June 30, 2026 dailymed.nlm.nih.gov
  3. Wilding JPH et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. PubMed 33567185
  4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. PubMed 33667417
  5. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6). Lancet Diabetes Endocrinol. 2022. PubMed 35131037
  6. Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025. PubMed 40961952
  7. Lingvay I et al. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025. PubMed 40961953
  8. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017. PubMed 28110911
  9. Frías JP et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE). Lancet Diabetes Endocrinol. 2021. PubMed 34293304
  10. US FDA, Drugs@FDA: OZEMPIC, NDA 209637 (original approval December 5, 2017) accessdata.fda.gov
  11. US FDA, Drugs@FDA: WEGOVY, NDA 215256 (original approval June 4, 2021) accessdata.fda.gov
  12. US FDA, supplement approval letter, NDA 215256/S-029 (Wegovy injection 7.2 mg weekly dose), March 19, 2026 accessdata.fda.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo